These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33974797)

  • 1. Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy.
    Cheng X; Xu HD; Ran HH; Liang G; Wu FG
    ACS Nano; 2021 May; 15(5):8039-8068. PubMed ID: 33974797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering nanomedicine for glutathione depletion-augmented cancer therapy.
    Xiong Y; Xiao C; Li Z; Yang X
    Chem Soc Rev; 2021 May; 50(10):6013-6041. PubMed ID: 34027953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy.
    Liu P; Hao L; Liu M; Hu S
    Front Bioeng Biotechnol; 2023; 11():1161472. PubMed ID: 36970628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy.
    Niu B; Liao K; Zhou Y; Wen T; Quan G; Pan X; Wu C
    Biomaterials; 2021 Oct; 277():121110. PubMed ID: 34482088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox Potential and ROS-Mediated Nanomedicines for Improving Cancer Therapy.
    Glass SB; Gonzalez-Fajardo L; Beringhs AO; Lu X
    Antioxid Redox Signal; 2019 Feb; 30(5):747-761. PubMed ID: 28990403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death.
    Wu F; Du Y; Yang J; Shao B; Mi Z; Yao Y; Cui Y; He F; Zhang Y; Yang P
    ACS Nano; 2022 Mar; 16(3):3647-3663. PubMed ID: 35266697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-Delivered and Self-Monitored Chemo-Photodynamic Nanoparticles with Light-Triggered Synergistic Antitumor Therapies by Downregulation of HIF-1α and Depletion of GSH.
    Zhang Z; Wang R; Huang X; Luo R; Xue J; Gao J; Liu W; Liu F; Feng F; Qu W
    ACS Appl Mater Interfaces; 2020 Feb; 12(5):5680-5694. PubMed ID: 31944660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimuli-activatable nanomedicines for chemodynamic therapy of cancer.
    Wang W; Jin Y; Xu Z; Liu X; Bajwa SZ; Khan WS; Yu H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1614. PubMed ID: 32011108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
    Chen G; Waxman DJ
    Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion.
    Wei G; Huang L; Jiang Y; Shen Y; Huang Z; Huang Y; Sun X; Zhao C
    Eur J Med Chem; 2019 May; 169():53-64. PubMed ID: 30856406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione in cancer biology and therapy.
    Estrela JM; Ortega A; Obrador E
    Crit Rev Clin Lab Sci; 2006; 43(2):143-81. PubMed ID: 16517421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
    Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
    Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimuli-responsive prodrug-based cancer nanomedicine.
    Xie A; Hanif S; Ouyang J; Tang Z; Kong N; Kim NY; Qi B; Patel D; Shi B; Tao W
    EBioMedicine; 2020 Jun; 56():102821. PubMed ID: 32505922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of glutathione in brain tumor drug resistance.
    Backos DS; Franklin CC; Reigan P
    Biochem Pharmacol; 2012 Apr; 83(8):1005-12. PubMed ID: 22138445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione-depleting nanoplatelets for enhanced sonodynamic cancer therapy.
    Huang C; Ding S; Jiang W; Wang FB
    Nanoscale; 2021 Mar; 13(8):4512-4518. PubMed ID: 33615325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambidextrous Approach To Disrupt Redox Balance in Tumor Cells with Increased ROS Production and Decreased GSH Synthesis for Cancer Therapy.
    Kou L; Sun R; Xiao S; Zheng Y; Chen Z; Cai A; Zheng H; Yao Q; Ganapathy V; Chen R
    ACS Appl Mater Interfaces; 2019 Jul; 11(30):26722-26730. PubMed ID: 31276364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione-Depleting Pro-Oxidant as a Selective Anticancer Therapeutic Agent.
    Yoo D; Jung E; Noh J; Hyun H; Seon S; Hong S; Kim D; Lee D
    ACS Omega; 2019 Jun; 4(6):10070-10077. PubMed ID: 31460099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.